Literature DB >> 26770384

Sitagliptin downregulates retinol-binding protein 4 and upregulates glucose transporter type 4 expression in a type 2 diabetes mellitus rat model.

Honglin Hu1, Min Xu1, Renjuan Qi1, Youmin Wang1, Changjiang Wang1, Jiongjiong Liu1, Li Luo1, Li Xia1, Zhaohui Fang2.   

Abstract

The present study was designed to investigate the effects of sitagliptin on metabolic parameters as well as the expression levels of retinol-binding protein 4 (RBP4) and glucose transporter type 4 (GLUT4) in a rat model of type 2 diabetes mellitus. A rat model of type 2 diabetes mellitus was established by a combination of a high-fat diet and intraperitoneal injection of low-dose streptozotocin. Rats were divided into three groups: normal control group, diabetes group, and diabetes + sitagliptin group. Body weight, glycemic parameters, lipid profiles, fasting insulin (FINS) and serum RBP4 levels were assessed at baseline and after 6 weeks of therapy. Western blotting was used to detect the tissue RBP4 and GLUT4 expression levels. After treatment for 6 weeks, the diabetes + sitagliptin group displayed significantly improve levels of blood sugar, blood grease, and insulin sensitizing functions (P < 0.05) than the diabetes group. Sitagliptin markedly down regulated RBP4 expression levels and up-regulated GLUT4 expression levels in adipose tissue and skeletal muscle. The results indicate that sitagliptin can modulate the RBP4-GLUT4 system in adipose tissue and skeletal muscle. Modulation of the RBP4-GLUT4 system may be one of the mechanisms by which sitagliptin ameliorates the symptoms of type 2 diabetes mellitus.

Entities:  

Keywords:  GLUT4; RBP4; Sitagliptin; type 2 diabetes mellitus

Year:  2015        PMID: 26770384      PMCID: PMC4694284     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  45 in total

Review 1.  Glucose transporters and insulin action--implications for insulin resistance and diabetes mellitus.

Authors:  P R Shepherd; B B Kahn
Journal:  N Engl J Med       Date:  1999-07-22       Impact factor: 91.245

Review 2.  Obesity and insulin resistance.

Authors:  B B Kahn; J S Flier
Journal:  J Clin Invest       Date:  2000-08       Impact factor: 14.808

3.  Sitagliptin reduces plaque macrophage content and stabilises arteriosclerotic lesions in Apoe (-/-) mice.

Authors:  F Vittone; A Liberman; D Vasic; R Ostertag; M Esser; D Walcher; A Ludwig; N Marx; M Burgmaier
Journal:  Diabetologia       Date:  2012-05-18       Impact factor: 10.122

4.  Retinol binding protein 4 as a candidate gene for type 2 diabetes and prediabetic intermediate traits.

Authors:  Rebekah L Craig; Winston S Chu; Steven C Elbein
Journal:  Mol Genet Metab       Date:  2006-12-14       Impact factor: 4.797

Review 5.  Adipose tissue as an endocrine organ.

Authors:  R S Ahima; J S Flier
Journal:  Trends Endocrinol Metab       Date:  2000-10       Impact factor: 12.015

6.  Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas.

Authors:  D A Stoffers; T J Kieffer; M A Hussain; D J Drucker; S Bonner-Weir; J F Habener; J M Egan
Journal:  Diabetes       Date:  2000-05       Impact factor: 9.461

7.  Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects.

Authors:  Timothy E Graham; Qin Yang; Matthias Blüher; Ann Hammarstedt; Theodore P Ciaraldi; Robert R Henry; Christopher J Wason; Andreas Oberbach; Per-Anders Jansson; Ulf Smith; Barbara B Kahn
Journal:  N Engl J Med       Date:  2006-06-15       Impact factor: 91.245

8.  Activators of AMP-activated protein kinase enhance GLUT4 translocation and its glucose transport activity in 3T3-L1 adipocytes.

Authors:  Shinya Yamaguchi; Hiroshi Katahira; Sachihiko Ozawa; Yoko Nakamichi; Toshiaki Tanaka; Tatsuhiro Shimoyama; Kazuto Takahashi; Katsuhiko Yoshimoto; Mica Ohara Imaizumi; Shinya Nagamatsu; Hitoshi Ishida
Journal:  Am J Physiol Endocrinol Metab       Date:  2005-05-31       Impact factor: 4.310

Review 9.  Gastric inhibitory polypeptide and glucagon-like peptide-1 in the pathogenesis of type 2 diabetes.

Authors:  Michael A Nauck; Birgit Baller; Juris J Meier
Journal:  Diabetes       Date:  2004-12       Impact factor: 9.461

10.  Effects of sitagliptin beyond glycemic control: focus on quality of life.

Authors:  Yoshiko Sakamoto; Jun-ichi Oyama; Hideo Ikeda; Shigetaka Kuroki; Shigeki Gondo; Taketo Iwamoto; Yasufumi Uchida; Kazuhisa Kodama; Atsushi Hiwatashi; Mitsuhiro Shimomura; Isao Taguchi; Teruo Inoue; Koichi Node
Journal:  Cardiovasc Diabetol       Date:  2013-02-21       Impact factor: 9.951

View more
  6 in total

Review 1.  Diabetes pharmacotherapy and effects on the musculoskeletal system.

Authors:  Evangelia Kalaitzoglou; John L Fowlkes; Iuliana Popescu; Kathryn M Thrailkill
Journal:  Diabetes Metab Res Rev       Date:  2018-12-20       Impact factor: 4.876

2.  Sitagliptin down-regulates retinol-binding protein 4 and reduces insulin resistance in gestational diabetes mellitus: a randomized and double-blind trial.

Authors:  Xia Sun; Zhendong Zhang; Hui Ning; Hong Sun; Xianghong Ji
Journal:  Metab Brain Dis       Date:  2017-02-17       Impact factor: 3.584

Review 3.  Interplay of retinol binding protein 4 with obesity and associated chronic alterations (Review).

Authors:  Yaccil Adilene Flores-Cortez; Martha I Barragán-Bonilla; Juan M Mendoza-Bello; Cecilia González-Calixto; Eugenia Flores-Alfaro; Mónica Espinoza-Rojo
Journal:  Mol Med Rep       Date:  2022-06-03       Impact factor: 3.423

4.  The Biological Impacts of Sitagliptin on the Pancreas of a Rat Model of Type 2 Diabetes Mellitus: Drug Interactions with Metformin.

Authors:  Lamiaa M Shawky; Ahmed A Morsi; Eman El Bana; Safaa Masoud Hanafy
Journal:  Biology (Basel)       Date:  2019-12-25

5.  Effect of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin on Muscle Mass and the Muscle/Fat Ratio in Patients With Type 2 Diabetes.

Authors:  Satoshi Ishii; Yoshio Nagai; Hiroyuki Kato; Hisashi Fukuda; Yasushi Tanaka
Journal:  J Clin Med Res       Date:  2020-02-01

6.  The therapeutic effects of berberine plus sitagliptin in a rat model of fatty liver disease.

Authors:  Soraya Mehrdoost; Parichehreh Yaghmaei; Hanieh Jafary; Azadeh Ebrahim-Habibi
Journal:  Iran J Basic Med Sci       Date:  2021-04       Impact factor: 2.699

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.